Otsuka Group News

Keyword search

Add search criteria

Search by company

Otsuka Holdings
Otsuka Pharmaceutical
Otsuka Pharmaceutical Factory
Taiho Pharmaceutical
Otsuka Warehouse
Otsuka Chemical
Otsuka Foods
Otsuka Medical Devices
Other

Search by category^*

Pharmaceuticals Business
Nutraceuticals Business
Consumer Products Business
Others
Products
R&D
Personnel
Corporate

* Business categories are based on the business segments described in the financial announcements.

Search by release date

-

Showing 93 results

Search by release date:: Jan, 2025 ～ Dec, 2025

December 22, 2025
Otsuka Foods

Otsuka Foods to Revise Prices of Some Products New Prices to Take Effect with Deliveries as of March 1, 2026
December 19, 2025
Otsuka Pharmaceutical

Otsuka Pharmaceutical Supports Anti-Doping Initiative “CLEAN SPORT NIPPON SELECT”
December 19, 2025
Otsuka Pharmaceutical

Otsuka Initiates Global Phase 3 Clinical Trial Evaluating Repinatrabit for the Treatment of Phenylketonuria (PKU)
December 13, 2025
Taiho Pharmaceutical

Results of the Phase 3 STAR-221 Study of Anti-TIGIT Antibody Domvanalimab and Anti-PD-1 Antibody Zimberelimab
December 2, 2025
Otsuka Pharmaceutical

Otsuka Launches Frailty Prevention Support VR as Newest Content in FACEDUO VR Program Portfolio -Enables earlier detection of frailty to support health maintenance and prevent or defer the need for nursing care-
November 28, 2025
Taiho Pharmaceutical

JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information ~Development of Shared Neoantigen Cancer Vaccines~
November 26, 2025
Otsuka Pharmaceutical

Otsuka Receives FDA Accelerated Approval for VOYXACT® (sibeprenlimab-szsi) for the Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy (IgAN) at Risk for Disease Progression
November 25, 2025
Otsuka Pharmaceutical

Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults
November 21, 2025
Otsuka Pharmaceutical

Otsuka launches NEXLETOL in Japan
November 21, 2025
Taiho Pharmaceutical

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of NDA to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
November 17, 2025
Otsuka Foods

Otsuka Foods Receives “Special Award” in the Food and Culture Awards,a First for a Food Manufacturer Recognized for Development Capabilities and Contributions as a Pioneer in Retort Foods
November 17, 2025
Otsuka Pharmaceutical

Donidalorsen Receives Positive CHMP Opinion for the Prevention of Hereditary Angioedema Attacks
November 10, 2025
Otsuka Holdings

Otsuka Group Establishes Solar Power Generation Facility in Donari, Tokushima as Its First Off-Site PPA Project to Promote Carbon Neutrality Initiatives
November 10, 2025
Otsuka Pharmaceutical

Sibeprenlimab Phase 3 Data Presented at American Society of Nephrology Kidney Week 2025 Showed Proteinuria Reduction through 12 Months for the Treatment of Immunoglobulin A Nephropathy (IgAN)
November 6, 2025
Otsuka Pharmaceutical

Otsuka Announces First Participants Enrolled in Phase 3 Clinical Trial Evaluating Investigational Compound Quabodepistat for Drug-resistant Pulmonary Tuberculosis
November 5, 2025
Otsuka Pharmaceutical

Otsuka Signs Joint Research Agreement in Japan with National Cerebral and Cardiovascular Center —Purpose Is to Evaluate Salt Reduction Behavior Change in Heart Disease Patients Using a Nutritional Monitoring App—
October 31, 2025
Otsuka Pharmaceutical

Otsuka Enters into Licensing Agreement for Ophthalmic Gene Therapy Drug Candidate 4D-150 (Anti-VEGF agent) ‐ Acquires Exclusive Development and Commercialization Rights for Asia-Oceania Region, Including Japan, from 4DMT ‐
October 31, 2025
Otsuka Medical Devices

Latest Real-World Clinical Data Demonstrate a 19.6 mmHg Reduction in Blood Pressure at 6 Months with Recor Medical’s Paradise Ultrasound Renal Denervation System (link to Recor website)
October 29, 2025
Otsuka Medical Devices

CMS Issues National Coverage Determination for Recor Medical’s Paradise Ultrasound Renal Denervation System for the Treatment of Hypertension (link to Recor website)
October 20, 2025
Taiho Pharmaceutical

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
October 16, 2025
Taiho Pharmaceutical

Taiho Pharma Enters Into Exclusive License Agreement with Haihe Biopharma for PI3Kα Inhibitor Risovalisib (CYH33)
October 10, 2025
Otsuka Holdings

Otsuka Holdings Publishes “Integrated Report 2025”
October 7, 2025
Otsuka Pharmaceutical

Research on Work Productivity Among Japanese Workers Published in the Journal of Occupational Health
September 24, 2025
Taiho Pharmaceutical

Taiho Pharmaceutical Enters Into Exploratory Collaboration with Guardant Health to Accelerate the Development of Therapies for Early-Stage, Recurrent Cancer Using Multimodal Real-World Data Including Genomic Profiling of MRD (Minimal Residual Disease)
September 20, 2025
Otsuka Pharmaceutical

Otsuka and Lundbeck Receive Complete Response Letter from U.S. FDA for sNDA of REXULTI (brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)
September 19, 2025
Otsuka Pharmaceutical

Otsuka Receives Approval in Japan for NEXLETOL® as a Treatment for Hypercholesterolemia
September 16, 2025
Otsuka Pharmaceutical

POCARI SWEAT × TOKUSHIMA VORTIS Football Dream Project Phase 5 Welcomed Junior Soccer Players from the Middle East to Tokushima for International Exchange
September 10, 2025
Otsuka Pharmaceutical

Joint Research on Athletes’ Heat Acclimatization and Fluid/Nutrition Strategies at the World Athletics Championships Tokyo 25 Provide New Insights for People Involved in Sports Around the World
September 3, 2025
Otsuka Pharmaceutical

Otsuka Pharmaceutical Supports World Athletics Championships Tokyo 25 with POCARI SWEAT "Believe In Your Potential." is the Key Message We are Spreading to People Around the World
September 2, 2025
Otsuka Holdings Taiho Pharmaceutical Other

Obituary: Notice Regarding the Passing of Yukio Kobayashi, Executive Advisor of Taiho Pharmaceutical